SynapDx is trying to develop a blood-based test that will catch most cases of autism spectrum disorders in children earlier than current methods (see “Can a Blood Test Detect Autism Early?”). The advantage would be that treatments seem to work better the sooner they start. The challenge is that there aren’t clear biomarkers or genetic signals for the disorder, which is most likely a mix of many different conditions.
But that doesn’t seem to deter sequencing giant Illumina, which has been growing the diagnostic side of its business over the last few months (see “A Brave New World of Prenatal DNA Sequencing”). According to the release:
“SynapDx and Illumina share a vision of better pediatric care through the use of advanced molecular assays and sequencing technologies,” said Stanley Lapidus, SynapDx’s CEO. “We look forward to broadly collaborating on multiple joint initiatives.”
SynapDx is currently recruiting participants into a clinical study of gene expression and autism in children less than 5 years old, which might help them identify biomarkers of the condition.
Meta has built a massive new language AI—and it’s giving it away for free
Facebook’s parent company is inviting researchers to pore over and pick apart the flaws in its version of GPT-3
The gene-edited pig heart given to a dying patient was infected with a pig virus
The first transplant of a genetically-modified pig heart into a human may have ended prematurely because of a well-known—and avoidable—risk.
Saudi Arabia plans to spend $1 billion a year discovering treatments to slow aging
The oil kingdom fears that its population is aging at an accelerated rate and hopes to test drugs to reverse the problem. First up might be the diabetes drug metformin.
Yann LeCun has a bold new vision for the future of AI
One of the godfathers of deep learning pulls together old ideas to sketch out a fresh path for AI, but raises as many questions as he answers.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.